mTOR, translation initiation and cancer
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a shift has been associated with proliferation in tumorigenesis, and has been linked to the translational control of RPs (Mamane et al., 2006; Ruggero and Sonenberg, 2005).”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Mamane et al., 2006
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 5×
“…factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for…”
BackgroundInfluentialSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“An important downstream target of this signaling pathway is cap-dependent mRNA translation (Hay and Sonenberg, 2004; Hennessy et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the…”
BackgroundeIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239 · cited 1×
“…Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994).”
BackgroundSelf-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 1×
“Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002, 2004).”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961 · cited 1×
“…et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004).”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956 · cited 1×
“…binding (Gingras et al., 1999b). eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cul- tured rodent cells (Lazaris-Karatzas et al., 1990).”
BackgroundSelf-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
Background
Cited by
Items 401–500 of 618
Clark, O., Park, I., Florio, A. D., Cichon, A.-C., Rustin, S., Jugov, R., Maeshima, R., & Stoker, A. W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.039 · Cited by 19
Translation control of mRNAs encoding mammalian translation initiation factors
Andreev, D. E., Dmitriev, S. E., Loughran, G., Terenin, I. M., Baranov, P. V., & Shatsky, I. N. (2018) · Gene · doi:10.1016/j.gene.2018.02.013 · Cited by 16
Kanaizumi, H., Higashi, C., Tanaka, Y., Hamada, M., Shinzaki, W., Azumi, T., Hashimoto, Y., Inui, H., Houjou, T., & Komoike, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9759 · Cited by 16
The rationale for mTOR inhibition in epithelial ovarian cancer
Trinh, X. B., van Dam, P. A., Dirix, L. Y., Vermeulen, P. B., & Tjalma, W. A. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321508 · Cited by 16
“Therefore, further research and interest has grown into using mTOR inhibitors as antitumoral agents [18-22].”
BackgroundReikvam, H., Hauge, M., Brenner, A. K., Hatfield, K. J., & Bruserud, Ø. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1032935 · Cited by 17
Chen, L., & Wang, H. (2019) · Toxicology · doi:10.1016/j.tox.2019.02.017 · Cited by 17
Chen, S., Feng, C., Yan, F., Zhou, X., Xu, L., Wang, W., Kong, X., Peppelenbosch, M. P., Pan, Q., & Yin, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071580 · Cited by 18
Tsai, A.-C., Pan, S., Lai, C.-Y., Wang, C.-Y., Chen, C.-C., Shen, C.-C., & Teng, C. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.04.014 · Cited by 16
“Unphosphorylated 4EBP is a translational inhibitor that binds to eukaryotic translation initiation factor 4E (eIF4E) to repress cap-dependent translation initiation [32].”
BackgroundKjellerup, R. B., Iversen, L., Kragballe, K., & Johansen, C. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09303.x · Cited by 16
Ear, T., Tatsiy, O., Allard, F. L., & McDonald, P. P. (2017) · Journal of Immunology Research · doi:10.1155/2017/4347121 · Cited by 18
“This again points towards translational control, given the known involvement of S6K, S6, and 4E-BP1 in cap-dependent protein translation in various cell types [30, 31].”
BackgroundLionello, M., Blandamura, S., Loreggian, L., Ottaviano, G., Giacomelli, L., Marchese‐Ragona, R., Velardita, C., Staffieri, A., & Marioni, G. (2011) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2011.01083.x · Cited by 15
“, inducing apoptosis and hindering cell cycle progression, cell growth, angiogenesis, endothelial cell proliferation, and protein translation (6, 8).”
BackgroundNiziolek, P., Murthy, S., Ellis, S. N., Sukhija, K. B., Hornberger, T. A., Turner, C. H., & Robling, A. G. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21887 · Cited by 16
“Activated mTOR phosphorylates p70S6-kinase 1 (p70S6k1) and 4E binding protein 1 (4E-BP1), leading to translation of proteins involved in cell proliferation and growth (Mamane et al., 2006; Manning and Cantley, 2007).”
Bouffant, R. L., Mulner‐Lorillon, O., Morales, J., Cormier, P., & Bellé, R. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700244h · Cited by 15
Chang, S.-H., Kim, J.-E., Lee, J.-H., Minai‐Tehrani, A., Han, K., Chae, C., Yh, C., Yun, J.-H., Park, K., Kim, Y.-S., et al. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.24 · Cited by 15
Guglielmelli, T., Giugliano, E., Brunetto, V., Rapa, I., Cappia, S., Giorcelli, J., Rrodhe, S., Papotti, M., & Saglio, G. N. (2015) · Oncoscience · doi:10.18632/oncoscience.148 · Cited by 19
“Phosphorylation of P70S6K stimulates ribosome biogenesis while multi-site phosphorylation of 4EBP1 results in its dissociation from elF4E thereby allowing elF4E to enhanced cap-dependent translation of oncogenic cap-mRNAs such as MYC, HIF-1 and Cyclin D1 [8-10].”
BackgroundAnomalous HIV-1 RNA, How Cap-Methylation Segregates Viral Transcripts by Form and Function
Boris‐Lawrie, K., Singh, G., Osmer, P. S., Zucko, D., Staller, S., & Heng, X. (2022) · Viruses · doi:10.3390/v14050935 · Cited by 15
“The global footprint of eIF4F activating cell growth underlies its frequent hyperregulation in malignancy and its antagonism by successful pathogens [76].”
BackgroundInfluentialDifferentiation-Induced Post-Transcriptional Control of B7-H1 in Human Trophoblast Cells
Holets, L. M., Carletti, M. Z., Kshirsagar, S., Christenson, L. K., & Petroff, M. G. (2008) · Placenta · doi:10.1016/j.placenta.2008.10.001 · Cited by 15
Xu, C., Jin, H., Lim, H.-T., Ha, Y.-C., Chae, C., An, G.-H., Lee, K.-H., & Cho, M. (2010) · Nutrition and Cancer · doi:10.1080/01635580903532432 · Cited by 16
“The Akt-mediated protein kinase controls cellular protein translation, and protein translation is closely related with cancer cell growth (30).”
BackgroundMalvezzi, P., Jouvé, T., & Rostaing, L. P. E. (2016) · Experimental and Clinical Transplantation · doi:10.6002/ect.2015.0292 · Cited by 15
Patel, M. R., Jay-Dixon, J., Sadiq, A. A., Jacobson, B. A., & Kratzke, R. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829ce963 · Cited by 14
“These findings lend more credence to the observation of numerous other investigators that mRNA translation is a major regulatory checkpoint in cancer cells, which is a legitimate target for cancer therapy.(25,26) Furthermore, in complex tumors with redundant signaling pathways, cap-dependent translation is an importan…”
Andreoli, A., Ruf, M. T., Itin, P. H., Pluschke, G., & Schmid, P. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13523 · Cited by 14
Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review
Karvelas, G., Roumpi, A., Komporozos, C., & Syrigos, K. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.01.013 · Cited by 16
Paíno, T., González-Méndez, L., San‐Segundo, L., Corchete, L. A., Hernández-García, S., Díaz-Tejedor, A., Algarín, E. M., Mogollón, P., Martín-Sánchez, M., Gutierrez, N. C., et al. (2020) · Cancers · doi:10.3390/cancers12102743 · Cited by 14
“It should be noted that mTORC1 controls global protein synthesis but, at the same time, previous studies have demonstrated that fluctuations of eIF4E levels mainly affect the translation of mRNAs harboring long, highly structured 5′-UTRs, which encode proteins that control cell proliferation and viability [19,26,27].”
BackgroundGenes up- and down-regulated by dermcidin in breast cancer: a microarray analysis
Moreira, D., Strauss, B. E., Vannier, E. G., & Belizário, J. E. (2008) · Genetics and Molecular Research · doi:10.4238/vol7-3x-meeting009 · Cited by 14
“Activation of the PI3K/AKT signaling pathway stimulates cell growth, proliferation and survival via the phosphorylation of a number of AKT substrates, including the FOXO family transcription factors, mTOR, the eIF4E-binding proteins and the ribosomal p70-S6 protein kinase (Mamane et al., 2006).”
BackgroundInfluentialOver-represented sequences located on 3' UTRs are potentially involved in regulatory functions
Yoon, K., Ko, D., Doderer, M. S., Livi, C. B., & Penalva, L. O. F. (2008) · RNA Biology · doi:10.4161/rna.7116 · Cited by 18
Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus
Çetin, B., Çoşkun, U., Yıldız, R., Buyukberber, S., Baykara, M., & Beneklı, M. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210363317 · Cited by 13
“The mTOR kinase also has some control over the angiogenic pathway through the hypoxia-inducible factor 1 alfa (HIF1a) and VEGF, and is linked to endothelial proliferation.(12,13) Thus, the inhibition or signal blockade of the mTOR kinase will in turn result in the cutoff of signals from the stress response signals, pr…”
BackgroundFound in translation of mTOR signaling
Clohessy, J. G., Reschke, M., & Pandolfi, P. P. (2012) · Cell Research · doi:10.1038/cr.2012.85 · Cited by 13
Lee, S., Kim, J., Hong, S., Lee, A.-Y., Park, E., Seo, H. W., Chae, C., Doble, P., Bishop, D., & Cho, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135582 · Cited by 15
“Another recent study found that the mTOR-Akt pathway was activated in approximately 90% of non-small cell lung cancer cells, which conferred survival and resistance to therapy [39].”
BackgroundMonitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly
Frosi, Y., Usher, R., Lian, D. T. G., Lane, D. P., & Brown, C. J. (2019) · BMC Biology · doi:10.1186/s12915-019-0658-0 · Cited by 14
IGFBP2 function as a novel biomarker for active lupus nephritis
Li, H., Liang, J. F., Gao, Y., Liu, M., Xia, N. L., Kong, W., Zheng, L., Zhang, Y., Li, Z., Chen, H., et al. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02241-z · Cited by 13
“*P 0.05 1 3 IGFBP2 blockade mediated the inhibition of mTOR phosphorylation which led to decreased level of phosphorylation of 4E-BP1, while there was no significant changes in protein and phosphorylation of RPS6KB1.”
BackgroundInfluentialZhang, X., WANG, Y., Wang, J., & Sun, F. (2015) · Oncology Reports · doi:10.3892/or.2015.4464 · Cited by 12
Melling, N., Simon, R., Izbicki, J. R., Terracciano, L., Bokemeyer, C., Sauter, G., & Marx, A. H. (2015) · Europe PMC (PubMed Central) · Cited by 12
Djakbarova, U., Marzluff, W. F., & Köseoğlu, M. M. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24686 · Cited by 12
“In G1, mTOR and MAPK pathways further boost the translation initiation machinery and are important for progression to S phase [Pyronnet and Sonenberg, 2001; Cormier et al., 2003; Mamane et al., 2006; Sivan and Elroy‐Stein, 2008].”
BackgroundKinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy
Dobashi, Y. (2010) · Frontiers in bioscience · doi:10.2741/3815 · Cited by 13
“Some of these exhibit potent activity even as a monotherapy, with minor toxicity against a wide panel of cancers, including renal cell carcinoma, SCLC, sarcoma, glioblastoma, and lymphoma (120), and everolimus has been approved for the treatment of renal cell carcinomas (119, 126).”
BackgroundmTOR inhibitors for treatment of low-risk prostate cancer
Liss, M. A., Rickborn, L., DiGiovanni, J., Bacich, D. J., deGraffenried, L. A., Parihar, M., Thompson, I. M., & Sharp, Z. D. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.004 · Cited by 13
Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans
Akins, R. A., & Sobel, J. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_29 · Cited by 15
Stickel, S., Gomes, N. P., & Su, T. T. (2014) · Proteomes · doi:10.3390/proteomes2020272 · Cited by 12
“Uninhibited Rheb then activates mTOR, which then regulates three key components involved in translation initiation: eIF4E, eIF4G, and S6 kinase (S6K) [37,42–45].”
BackgroundXu, L., Zhang, H., Mei, M., Du, C., Huang, X., Li, J., Wang, Y., Bao, S., & Zheng, H. (2018) · Cancer Science · doi:10.1111/cas.13834 · Cited by 12
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Altintas, D. M., & Comoglio, P. M. (2023) · Cancers · doi:10.3390/cancers15184672 · Cited by 11
Wittenstein, A., Caspi, M., Rippin, I., Elroy‐Stein, O., Eldar-Finkelman, H., Thoms, S., & Rosin‐Arbesfeld, R. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002355 · Cited by 11
Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation
Kratzke, R. A. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1252 · Cited by 13
“The major downstream targets of mTOR are p70 S6 kinase (p70S6K) and 4E-BP1 (18).”
BackgroundKanaizumi, H., Higashi, C., Tanaka, Y., Hamada, M., Shinzaki, W., Hashimoto, Y., Inui, H., Houjou, T., & Komoike, Y. (2018) · European Journal of Cancer · doi:10.1016/s0959-8049(18)30502-1 · Cited by 11
EIF4E regulates STEAP1 expression in peritoneal metastasis
Jiang, J., Wu, Y., Fang, X., & Ji, F. (2019) · Journal of Cancer · doi:10.7150/jca.29105 · Cited by 13
“Post-transcriptional regulation of gene expression in cancer progression is well documented [26], and have led to two regulatory roles for this process in cancer [27, 28].”
BackgroundFrosi, Y., Lin, Y., Jiang, S., Ramlan, S. R., Hew, K., Engman, A. H., Pillai, A., Yeung, K., Cheng, Y. X., Cornvik, T. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32463-1 · Cited by 12
Insulin Signaling Augments eIF4E-Dependent Nonsense-Mediated mRNA Decay in Mammalian Cells
Park, J., Ahn, S.-Y., Jayabalan, A. K., Ohn, T., Koh, H. C., & Hwang, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.12.006 · Cited by 11
Tan, G. M. Y., Lim, H. J., Yeow, T. C., Movahed, E., Looi, C. Y., Gupta, R., Arulanandam, B. P., AbuBakar, S., Sabet, N. S., Chang, L., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201500219 · Cited by 11
“mTOR is a Ser/Thr kinase which can form mTOR complex 1 (mTORC1) to control translation initiation [26].”
BackgroundP-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis
Ding, X., Li, L., Zhou, X., Guo, L., Dou, M., Chi, Y.-Y., Wu, S., Zhang, Y., Shan, Z., Zhang, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170302 · Cited by 11
Chumsri, S., Zhao, M. Y., Garofalo, M. C., Burger, A. M., Hamburger, A. W., Zhao, F. X., & Rapoport, A. P. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701809214 · Cited by 11
“The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that regulates cell proliferation and survival [1,2].”
BackgroundInhibition of TIGIT on NK cells improves their cytotoxicity and HIV reservoir eradication potential
Wang, Y., Li, Y., Chen, J., Guo, C., Yu, X., Zhang, Z., Fu, Y., Han, X., Hu, Q., Ding, H., et al. (2025) · mBio · doi:10.1128/mbio.03226-24 · Cited by 11
“In previous reports, mice infected with MCMV and treated with the mTOR inhibitor rapamycin exhibited impaired proliferation and reduced IFN-γ production by NK cells (58, 59).”
Demirkesen, Ş., İriağaç, Y., Seber, S., & Aral, C. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00907-1 · Cited by 11
“Previous research has shown that combining everolimus with other drugs causes cell cycle arrest in the G0/G1 phase in MCF-7, BT474 and K562 cells [33, 34] as well as in the G2/M phase in MCF-7 cells when everolimus is combined with ribociclib [35].”
Association of ribosomal protein S6 kinase 1 with cellular radiosensitivity of non-small lung cancer
Wang, Y., Mei, H., Shao, Q., Wang, J., & Lin, Z. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1294273 · Cited by 10
“…kinase S6K1 that acts downstream of the mammalian target of rapamycin (mTOR) plays a critical role in regulating a wide variety of cellular processes including translation initiation, ribosome biogenesis, lipid synthesis, and cell growth (Mamane et al. 2006; Yuan et al. 2013; Chauvin et al. 2014).”
BackgroundTseng, D.-Y., Wang, S., Ballantyne, R., & Liu, C. (2023) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2023.108884 · Cited by 11
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer
Zhang, Q.-Y., Cheng, W., Li, W.-M., Au, W. W., & Lu, Y. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.07.007 · Cited by 10
Jh, Z., Seigneur, E. M., Pandey, M., Loshakov, A., Dagur, P. K., Connelly, P. S., Koo, L. Y., Panicker, L. M., & Simonds, W. F. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.6 · Cited by 10
“One well-characterized effector of mTOR is the eukaryotic translation initiation factor 4E-binding protein (eIF4EBP or 4E-BP) that competes with eIF-4G for binding to eIF-4E to inhibit mRNA cap-dependent translational initiation.(27,28) Phosphorylation of eIF4EBP by mTOR reduces its affinity for eIF-4E and promotes th…”
Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1
Redondo, N., García-Moreno, M., Sanz, M. Á., & Carrasco, L. (2013) · Virology · doi:10.1016/j.virol.2013.06.008 · Cited by 13
“The rate-limiting factor of the eIF4F complex is eIF4E, whose involvement in translation is regulated by the PI3K/Akt/mTOR pathway (Gingras et al., 1999; Mamane et al., 2006).”
Dlamini, Z., Shoba, B., & Hull, R. (2020) · PubMed · Cited by 10
Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer
Pérez, I., Blanco, L., Sanz, B., Errarte, P., Ariz, U., Beitia, M., Fernández‐Atutxa, A., Loizate, A., Candenas, L., Pinto, F. M., et al. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11808 · Cited by 10
“Besides, this lack of correlation is widely spread in renal diseases involving altered energy metabolism like diabetes-induced renal hypertrophy, diabetes-induced matrix synthesis or angiotensin II induced renal injury, and hence, it could be a strong possibility for cancer cells to show this discrepancy [38-41].”
BackgroundZhong, X., Persaud, L., Muharam, H., Francis, A. M., Das, D. K., Aktas, B. H., & Sauane, M. (2018) · Cancers · doi:10.3390/cancers10050153 · Cited by 12
Higurashi, T., Arimoto, J., Ashikari, K., Takatsu, T., Misawa, N., Yoshihara, T., Matsuura, T., Fuyuki, A., Ohkubo, H., & Nakajima, A. (2020) · BMC Cancer · doi:10.1186/s12885-020-07564-z · Cited by 10
Nangia, V., Ashraf, H. M., Marikar, N. C., Passanisi, V. J., Christopher, R., & Spencer, S. L. (2025) · Science Signaling · doi:10.1126/scisignal.adw3231 · Cited by 11
Leclerc, D., Dejgaard, K., Mazur, A. M., Deng, L.-Y., Wu, Q. H., Nilsson, T., & Rozen, R. R. (2014) · PROTEOMICS · doi:10.1002/pmic.201400280 · Cited by 9
“Interestingly, methylation and expression changes related to insulin resistance-related genes, including PDK4 were observed in the normal intestine of CRC patients [21, 31].”
BackgroundInfluentialReversal of memory and autism-related phenotypes in Tsc2+/− mice via inhibition of Nlgn1
Chalkiadaki, K., Statoulla, E., Zafeiri, M., Haji, N., Lacaille, J., Powell, C. M., Jafarnejad, S. M., Khoutorsky, A., & Gkogkas, C. G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1205112 · Cited by 9
“The best ascribed function of mTORC1 signaling is regulation of mRNA translation via phosphorylation of two major downstream effectors: 4E-BPs (eukaryotic initiation factor 4Ebinding proteins 1, 2 and 3) and S6Ks (ribosomal protein S6 kinases 1 and 2), which regulate cap-dependent initiation of translation (Mamane et…”
BackgroundBates, J. G., Salzman, J., May, D., Garcia, P. B., Hogan, G. J., McIntosh, M. W., Schlissel, M. S., & Brown, P. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037108 · Cited by 10
“the mTOR pathway [31,32].”
Spreading of mesothelioma cells is rapamycin‐sensitive and requires continuing translation
Ranzato, E., Grosso, S., Patrone, M., Betta, P. G., Viarengo, A., & Biffo, S. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22316 · Cited by 11
“The mTOR pathway regulates cap-dependent translation in cancer cells [Mamane et al., 2006].”
BackgroundInfluentialThe coordinated management of ribosome and translation during injury and regeneration
Nguyen, T., Mills, J. C., & Cho, C. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1186638 · Cited by 9
“mTORC1 is a well-known factor for sensing nutrients and is also linked to cellular growth and proliferation in various species, including multiple phyla of animals (Mamane et al., 2006), plants (Chen et al.”
BackgroundHuang, K., Gao, L., Yang, M., Wang, J., Wang, Z., Wang, L., Wang, G., & Li, H. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.05.020 · Cited by 9
Ato, S., Kido, K., Sase, K., & Fujita, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00469 · Cited by 9
A Study of Epstein-Barr Virus BRLF1 Activity in aDrosophilaModel System
Adamson, A. L., & LaJeunesse, D. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/347597 · Cited by 9
“We are especially interested in the mammalian mTOR pathway, which controls cell growth and protein translation [19] and how it will affect R and Z functioning during EBV lytic replication, as well as the mammalian Rab5 protein, and how vesicle trafficking may affect or be affected by EBV lytic replication.”
BackgroundBaskarapantula, S. S., Kumar, V. S., Changdar, P., Chakraborty, D., Nayak, Y., Spada, A. R. L., Bennett, C. L., & Dastidar, S. G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05553-6 · Cited by 9
“The ribosome binds at the 5’ cap (m 7 GpppN, where N can be any nucleotide) end of the mRNA, which is aided by different initiation factors [14].”
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas
Mohindra, N. A., & Agulnik, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1076792 · Cited by 9
“The mTOR pathway plays an integral role in cellular growth, metabolism, and proliferation by controlling protein synthesis in response to growth stimuli and environmental signals [42-46].”
BackgroundLópez-Beltrán, A., Kırkalı, Z., Cheng, L., Egevad, L., Regueiro, J. C., Blanca, A., & Montironi, R. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.07.006 · Cited by 8
Sugimoto, T., Imai, S., Yoshikawa, M., Fujisato, T., Hashimoto, T., & Nakamura, T. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00323.2021 · Cited by 9
SP600125 Inhibits Cap-dependent Translation Independently of the c-Jun N-terminal Kinase Pathway
Ito, M., Kitamura, H., Kikuguchi, C., Hase, K., Ohno, H., & Ohara, O. (2011) · Cell Structure and Function · doi:10.1247/csf.10025 · Cited by 8
“mTOR directly phosphorylates two translational regulators, namely 4E-binding protein 1 (4EBP1) and p70 ribosomal protein S6 kinase (S6K), and subsequently activates translation initiation factors such as eukaryotic initiation factor (eIF) 4B and eIF4E (Ma and Blenis, 2009; Mamane et al., 2006).”
BackgroundGermano, C. A., Clemente, G., Storniolo, A., Romeo, M. A., Ferretti, E., Cirone, M., & Renzo, L. D. (2023) · Biology · doi:10.3390/biology12050676 · Cited by 10
“mTORC1 is essential in regulating the cap-dependent translation initiation of many proteins through the phosphorylation of p70 ribosomal protein S6 kinase (P70S6K) and that of the inhibitor of protein synthesis eukaryotic translation initiation factor 4E (eIF4E) binding protein 1, known as 4EBP1 [6,7].”
BackgroundMitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein
Egervári, G., Márk, Á., Hajdú, M., Barna, G., Sápi, Z., Krenács, T., Kopper, L., & Sebestyén, A. R. (2011) · Histochemistry and Cell Biology · doi:10.1007/s00418-011-0803-5 · Cited by 8
“growth and cell cycle progression (Fingar et al. 2004; Mamane et al. 2006).”
BackgroundRNA interference targeting raptor inhibits proliferation of gastric cancer cells
Wu, W. K. K., Lee, C. W., Cho, C. H., Chan, F. K. L., Yu, J. Q., & Sung, J. J. �. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.005 · Cited by 8
Role of everolimus in the treatment of renal cell carcinoma
George, S., & Bukowski (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4895 · Cited by 8
“The mTOR kinase also has some control over the angiogenic pathway through the hypoxiainducible factor 1 alfa (HIF1α) and VEGF and is linked to endothelial proliferation.(12,13) Thus the inhibition or signal blockade of the mTOR kinase will in turn result in the cutoff of signals from the stress response signals, preve…”
Use of mTOR inhibitors in the treatment of malignancies
Mohindra, N. A., Giles, F. J., & Platanias, L. C. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.899582 · Cited by 7
“As mentioned above, the mTOR pathway controls cell metabolism, proliferation, and angiogenesis by regulating protein synthesis in response to environmental cues, nutrient availability, and growth signals [21-25].”
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
Yasugi, M., Takigawa, N., Ochi, N., Ohashi, K., Harada, D., Ninomiya, T., Murakami, T., Honda, Y., Ichihara, E., Tanimoto, M., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.012 · Cited by 6
Somlo, S., & Guay‐Woodford, L. M. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-449851-8.00024-3 · Cited by 9
An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
Altintas, D. M., Cerqua, M., Laurentiis, A. D., Trusolino, L., Boccaccio, C., & Comoglio, P. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-28648-3 · Cited by 7
Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia
Stokłosa, T., Głodkowska‐Mrówka, E., Hoser, G., Kielak, M., Seferyńska, I., & Wlodarski, P. K. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.02.001 · Cited by 7
“Both of these targets, when phosphorylated by TORC1, promote translation of mRNA critical for cell growth [15].”
BackgroundImproving outcomes in patients with advanced renal cell carcinoma
Sosman, J. A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.481 · Cited by 7
MCM8 promotes gastric cancer progression through RPS15A and predicts poor prognosis
Ding, L., Sun, M., Yanyan, S., Li, J., Zhang, Z., Dang, S., Zhang, J., Yang, B., Dai, Y., Zhou, Q., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7424 · Cited by 6
“49,50 53 Activated RPS6 and RPS15A promote ribosome function in GC cell.”
Protein Kinase C Epsilon and Genetic Networks in Osteosarcoma Metastasis
Goudarzi, A., Gökgöz, N., Gill, M., Pinnaduwage, D., Merico, D., Wunder, J. S., & Andrulis, I. L. (2013) · Cancers · doi:10.3390/cancers5020372 · Cited by 6
“Increased or over-active translation is known to support an aggressive phenotype of many cancers [115], and the analysis presented here implies it is a characteristic of MD-OS tumors as well.”
BackgroundInsulin-induced mTOR activity exhibits anti-hepatitis C virus activity
Muraoka, T., Ichikawa, T., Taura, N., Miyaaki, H., Takeshita, S., Akiyama, M., Miuma, S., Ozawa, E., Isomoto, H., Takeshima, F., et al. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.662 · Cited by 6
“Although mTOR is a mRNA translational regulator that acts through phosphorylation of a downstream target such as 4E-BP and S6K (22), IFN-induced mTOR activity influences the phosphorylation of STAT-1 (13).”
BackgroundRuff, A., Lewis, M., & Whalen, M. M. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03413-z · Cited by 7
Saeki, K., Watanabe, M., Michishita, M., Tsuboi, M., Sugano, S., Yoshitake, R., Murai, K., Tanaka, Y., Ong, S. M., Saito, T., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.025 · Cited by 7
Weighing up the possibilities: Controlling translation by ubiquitylation and sumoylation
Watts, F. Z., Baldock, R. A., Jongjitwimol, J., & Morley, S. (2014) · Translation · doi:10.4161/2169074x.2014.959366 · Cited by 6
“eIF4E Regulation of eIF4E levels is important for normal cell growth, as disruption of its expression or its over-production leads to aberrant cell growth or oncogenesis.(38) Additionally,”
BackgroundDyer, J., & Sossin, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074085 · Cited by 7
“In many cases, translational control is studied in the context of cell size and cell proliferation, since in most cell lines and in cancerous cells, translational control is critical in determining whether or not the cell decides to double its proteome and divide [1,2].”
BackgroundThe Roles of Ras Family Small GTPases in Breast Cancer
Hanker, A. B., & Der, C. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00322-3 · Cited by 6
Opdenaker, L. M., & Farach‐Carson, M. C. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22145 · Cited by 6
“Some of these transcripts include VEGF, HIF1a, cyclin D1, FGF2, and c-myc; all of which are involved in cell growth, proliferation and transformation [reviewed in Mamane et al., 2006].”
BackgroundMukherjee, A., Koli, S., & Reddy, K. V. R. (2015) · Andrology · doi:10.1111/andr.12075 · Cited by 5
“Members of the EIF4E-binding proteins (4E-BPs), a family of translational repressors, compete with EIF4G for binding with EIF4E, thus contribute to the regulation of EIF4F complex formation and transcription initiation (Haghighat et al., 1995; Mader et al., 1995; Mamane et al., 2006).”
BackgroundA new IRES-mediated truncated Cx32 isoform inhibits global mRNA translation to suppress glioblastoma
Cai, S., Peng, F., Tang, H., Zhou, L., Chen, Z., Wu, P., Ou, Y., Tao, L., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114513 · Cited by 6
Feng, S.-W., Wu, Z.-S., Chiu, Y., & Huang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119256 · Cited by 5
Translational Control of Cancer: Implications for Targeted Therapy
Bitterman, P. B., & Polunovsky, V. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_12 · Cited by 6
“lational apparatus and intracellular levels of some cancer-related proteins such cyclin D1, c-Myc, Ras, and VEGF [111].”
BackgroundMurata, K., Villena, J., Tomosada, Y., Hara, R., Chiba, E., Shimazu, T., Aso, H., Suda, Y., Iwabuchi, N., Xiao, J., et al. (2013) · Open Journal of Veterinary Medicine · doi:10.4236/ojvm.2013.32023 · Cited by 5
“It has been demonstrated that TGF-β rapidly induces ERK1 activity in IECs and that this TGF-β and ERK interaction regulates gene expression that is crucial for cell growth and survival of IECs as well as IECs migration [32,33].”
BackgroundYu, Z.-J., Luo, H.-H., Shang, Z., Guan, H., Xiao, B.-B., Liu, X.-D., Wang, Y., Huang, B., & Zhou, P. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.18329 · Cited by 5
“The PI3K-Akt-mTOR signal pathway plays the major role in phosphorylating 4E-BP1 [4].”
BackgroundChinen, Y., Tsukamoto, T., Maegawa, S., Matsumura‐Kimoto, Y., Takimoto‐Shimomura, T., Tanba, K., Mizuno, Y., Fujibayashi, Y., Kuwahara‐Ota, S., Shimura, Y., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.02.004 · Cited by 5
Fonseca, B. D., & Proud, C. G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_9 · Cited by 5
“The links between eIF4E and tumorigenesis have been the subject of several recent and informative reviews [43–48].”
Metadata
- Authors
- Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N.
- Affiliations
- McGill University (CA)
- Corresponding author
- Sonenberg, N
- ORCID
- Sonenberg, N
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6416-6422
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2165848665
- Cited by
- 607
- References
- 79
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 28 · 2022: 14 · 2021: 7 · 2020: 23 · 2019: 16 · 2018: 32 · 2017: 26 · 2016: 28 · 2015: 41 · 2014: 41 · 2013: 40 · 2012: 41
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTOR, mRNA translation, translation initiation, PI3K/AKT/mTOR pathway, 4E-BP, S6K, cap-dependent translation, cancer therapy, nutrient signaling, cell growth
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Mammals, Models, Genetic, Neoplasms, Peptide Chain Initiation, Translational, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.